Creation and validation of models to predict response to primary treatment in serous ovarian cancer
Abstract Nearly a third of patients with high-grade serous ovarian cancer (HGSC) do not respond to initial therapy and have an overall poor prognosis. However, there are no validated tools that accurately predict which patients will not respond. Our objective is to create and validate accurate model...
Guardado en:
Autores principales: | Jesus Gonzalez Bosquet, Eric J. Devor, Andreea M. Newtson, Brian J. Smith, David P. Bender, Michael J. Goodheart, Megan E. McDonald, Terry A. Braun, Kristina W. Thiel, Kimberly K. Leslie |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f68931067a254b7db52a837c8291c2da |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
por: Jennifer Ducie, et al.
Publicado: (2017) -
High grade serous ovarian carcinomas originate in the fallopian tube
por: S. Intidhar Labidi-Galy, et al.
Publicado: (2017) -
Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma
por: Shuang Zhang, et al.
Publicado: (2019) -
Why the dual origins of high grade serous ovarian cancer matter
por: Emily K. Colvin, et al.
Publicado: (2020) -
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer
por: Aritro Nath, et al.
Publicado: (2021)